Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16576239 | 0.92 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL12729681 | 0.91 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL14280412 | 0.89 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL14549227 | 0.88 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL14280415 | 0.87 | MAPK14 (0.73) | MAPK14MAPK11 | |
| SCHEMBL14280414 | 0.87 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL12729679 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL12663458 | 0.85 | MAPK14 (0.88) | MAPK14MAPK11 | |
| SCHEMBL12729703 | 0.85 | MAPK14 (0.91) | MAPK14MAPK11 | |
| SCHEMBL12779818 | 0.85 | MAPK14 (0.91) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572795-B2 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-18 | — | — | US | disclosed |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | MAPK14 369/4885MAPK11 232/4885 |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | MAPK14 371/4885MAPK11 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.